Merck (MRK) Capital Expenditures (2009 - 2026)

Merck has disclosed Capital Expenditures across 18 years of filings, most recently posting $991.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 25.38% year-over-year to $991.0 million; the TTM figure through Mar 2026 stood at $3.8 billion (down 1.67% YoY), while the FY2025 annual figure was $4.1 billion, up 21.95% from the prior year.
• Capital Expenditures retreated to $991.0 million in Q1 2026, from $1.0 billion in the prior quarter.
• Over the last five years, Capital Expenditures for MRK reached as high as $1.3 billion in Q1 2025 and fell as low as $764.0 million in Q2 2025.
• The 5-year median for Capital Expenditures is $987.0 million (2025), against an average of $983.9 million.
• Annual changes were most pronounced in 2025 — Capital Expenditures jumped 54.24% — and 2026, when it slipped 25.38%.
• A 5-year view of Capital Expenditures shows it stood at $1.1 billion in 2022, then decreased by 13.93% to $989.0 million in 2023, then retreated by 5.26% to $937.0 million in 2024, then gained by 10.25% to $1.0 billion in 2025, then declined by 4.07% to $991.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $991.0 million, $1.0 billion, and $987.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.